Skip to main content
38°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
22.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
22.27
Bid (Size)
21.81 (1)
Ask (Size)
35.40 (1)
Prev. Close
22.27
Today's Range
22.27 - 22.27
52wk Range
13.36 - 41.31
Shares Outstanding
27,433,359
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Anaptys Announces Participation in November and December Investor Conferences
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
November 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Performance
YTD
+2.63%
+2.63%
1 Month
-30.47%
-30.47%
3 Month
-40.33%
-40.33%
6 Month
-4.67%
-4.67%
1 Year
+60.22%
+60.22%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 30, 2024
Via
Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
October 21, 2024
Via
Benzinga
What Analysts Are Saying About AnaptysBio Stock
September 26, 2024
Via
Benzinga
Insiders Buying Yum China And 2 Other Stocks
August 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
Anaptys Announces Participation in September Investor Conferences
August 29, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Why AnaptysBio Was Such a Healthy Stock This Week
August 23, 2024
Via
The Motley Fool
4 Analysts Assess AnaptysBio: What You Need To Know
August 06, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On AnaptysBio
May 10, 2024
Via
Benzinga
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
August 14, 2024
Via
Benzinga
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
Via
Investor's Business Daily
S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday
August 14, 2024
Via
Benzinga
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 14, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
August 05, 2024
Via
InvestorPlace
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
Via
Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.